Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials

Visipaque (iodixanol)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved April 1996

Specific Treatments:

diagnosis of disease in major organs

General Information

Visipaque is a contrast agent that allows doctors to better diagnose diseases of the heart, brain, kidney, blood vessels and other major organs.

Additional Information

Contrast agents, in general, are fluids that are injected into a subject's blood stream to enhance the images, or pictures, of certain body organ structures or processes obtained during diagnostic imaging procedures. This enhancement enables physicians to more accurately detect, diagnose, and properly treat disease, states, and functional abnormalities, such as tumors and cardiovascular disorders.

Each year, as many as 18 million subjects in the United States undergo X-rays and other diagnostic procedures that require the administration of contrast media to aid in the detailed visualization of internal organs and tissues.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation